Scorpion Capital shorts TransMedics, shares down
Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...
Scorpion Capital shorts TransMedics, alleging fraud in report
Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...
Why TransMedics Group Stock Is Tanking Today
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...
TransMedics down 10% to $65.39 after Scorpion Capital short report
EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...
TransMedics Shares Plunge Following Short Seller Allegations
The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...
Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX
NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...
TransMedics named as short idea with $0 target by Scorpion Capital
Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...
TransMedics: A Cash Burn Problem That's Hard To Ignore
TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...
Harvard Business School2y
Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues
Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022.
Nasdaq1mon
TransMedics price target lowered to $120 from $150 at Baird
Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $120 from $150 and keeps an Outperform rating on the shares. The firm said at the company’s inaugural ...